HealthEquity (NASDAQ:HQY) Stock Rating Reaffirmed by Barrington Research

HealthEquity (NASDAQ:HQY)‘s stock had its “outperform” rating reaffirmed by investment analysts at Barrington Research in a report released on Friday, Benzinga reports. They currently have a $105.00 price objective on the stock. Barrington Research’s target price would indicate a potential upside of 31.98% from the company’s current price.

A number of other analysts have also commented on HQY. JMP Securities boosted their price target on HealthEquity from $101.00 to $105.00 and gave the company a “market outperform” rating in a report on Tuesday, June 4th. Royal Bank of Canada restated an “outperform” rating and issued a $92.00 target price on shares of HealthEquity in a research note on Tuesday, June 4th. KeyCorp raised their price target on shares of HealthEquity from $95.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 5th. Wells Fargo & Company boosted their price objective on shares of HealthEquity from $107.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, June 20th. Finally, Robert W. Baird increased their target price on shares of HealthEquity from $98.00 to $104.00 and gave the stock an “outperform” rating in a report on Tuesday, June 4th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $101.67.

HealthEquity Price Performance

Shares of HQY stock opened at $79.56 on Friday. The firm’s 50 day moving average price is $77.47 and its two-hundred day moving average price is $79.72. The stock has a market cap of $6.92 billion, a PE ratio of 86.48, a PEG ratio of 1.31 and a beta of 0.57. HealthEquity has a 52-week low of $61.81 and a 52-week high of $88.26. The company has a debt-to-equity ratio of 0.44, a quick ratio of 4.39 and a current ratio of 4.39.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings data on Monday, June 3rd. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.08. HealthEquity had a net margin of 7.71% and a return on equity of 7.77%. The business had revenue of $287.60 million for the quarter, compared to analyst estimates of $278.78 million. As a group, analysts forecast that HealthEquity will post 2.12 EPS for the current year.

Insider Activity at HealthEquity

In related news, Vice Chairman Stephen Neeleman sold 35,000 shares of HealthEquity stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $79.86, for a total value of $2,795,100.00. Following the transaction, the insider now directly owns 89,769 shares of the company’s stock, valued at $7,168,952.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Jon Kessler sold 32,326 shares of HealthEquity stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $82.83, for a total transaction of $2,677,562.58. Following the sale, the chief executive officer now directly owns 232,176 shares of the company’s stock, valued at approximately $19,231,138.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Vice Chairman Stephen Neeleman sold 35,000 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the transaction, the insider now owns 89,769 shares of the company’s stock, valued at $7,168,952.34. The disclosure for this sale can be found here. Insiders sold a total of 77,511 shares of company stock valued at $6,314,446 over the last quarter. 2.20% of the stock is owned by corporate insiders.

Institutional Trading of HealthEquity

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in HealthEquity by 1.7% in the first quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company’s stock valued at $715,783,000 after purchasing an additional 149,133 shares during the period. Wasatch Advisors LP increased its stake in shares of HealthEquity by 8.3% in the first quarter. Wasatch Advisors LP now owns 7,409,080 shares of the company’s stock valued at $604,803,000 after buying an additional 569,249 shares during the period. Motley Fool Asset Management LLC raised its position in shares of HealthEquity by 3,001.0% during the first quarter. Motley Fool Asset Management LLC now owns 3,762,064 shares of the company’s stock worth $307,097,000 after acquiring an additional 3,640,748 shares during the last quarter. Clearbridge Investments LLC lifted its stake in shares of HealthEquity by 1.9% in the second quarter. Clearbridge Investments LLC now owns 2,377,204 shares of the company’s stock worth $204,915,000 after acquiring an additional 43,491 shares during the period. Finally, Mackenzie Financial Corp boosted its holdings in HealthEquity by 16.0% in the second quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company’s stock valued at $203,822,000 after acquiring an additional 325,906 shares during the last quarter. 99.55% of the stock is owned by institutional investors and hedge funds.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.